Payment overview · 2025
General Payments
$1,028.23
49 reported records · 14 companies
Healthcare provider profile · identity verified
Kirk Douglas Jacobson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EUGENE, OR · NPI 1093707366
Verified facts
What the public records show
CMS Open Payments records show Kirk Douglas Jacobson, M.D. received $1,028.23 in general payments during 2025 across 49 reported records.
PFIZER INC. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 422 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 422 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $161.70 | 15.7% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $146.37 | 14.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $143.89 | 14.0% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $127.72 | 12.4% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.16 | 8.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.03 | 7.6% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $69.62 | 6.8% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $63.22 | 6.2% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $41.75 | 4.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $36.52 | 3.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$27.20 | 2.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.71 | 2.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.80 | 1.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $7.54 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,012.24 | 48 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $146.37 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $143.38 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $136.26 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $130.38 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $130.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $119.16 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $85.16 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $84.93 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $69.62 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $63.22 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.40 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.44 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.44 | 6 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.02 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $7.54 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $3.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 422 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 212 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
422 | 101 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
212 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
422 | 101 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 740 | 191 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 714 | 199 |
| Atorvastatin Calcium | Atorvastatin Calcium | 639 | 171 |
| Irbesartan | Irbesartan | 618 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 131 |
| Gabapentin | Gabapentin | 425 | 118 |
| Eliquis | Apixaban | 422 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 416 | 118 |
| Simvastatin | Simvastatin | 358 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 352 | 95 |
| Omeprazole | Omeprazole | 293 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 271 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 74 |
| Carvedilol | Carvedilol | 233 | 68 |
| Lisinopril | Lisinopril | 230 | 63 |
| Meloxicam | Meloxicam | 222 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 60 |
| Potassium Chloride | Potassium Chloride | 214 | 55 |
| Ozempic | Semaglutide | 212 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 206 | 56 |
| Alprazolam | Alprazolam | 196 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 187 | 74 |
| Tramadol Hcl | Tramadol Hcl | 180 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 178 | 46 |
| Losartan Potassium | Losartan Potassium | 177 | 53 |
| Trazodone Hcl | Trazodone Hcl | 169 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 44 |
| Furosemide | Furosemide | 155 | 45 |
| Oxycodone Hcl | Oxycodone Hcl | 150 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 43 |
| Allopurinol | Allopurinol | 144 | 45 |
| Lovastatin | Lovastatin | 137 | 33 |
| Estradiol | Estradiol | 125 | 43 |
| Telmisartan | Telmisartan | 125 | 34 |
| Celecoxib | Celecoxib | 123 | 44 |
| Levofloxacin | Levofloxacin | 117 | 89 |
| Lorazepam | Lorazepam | 115 | 27 |
| Metformin Hcl | Metformin Hcl | 114 | 34 |
| Clonazepam | Clonazepam | 104 | 18 |
| Montelukast Sodium | Montelukast Sodium | 96 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 27 |
| Prednisone | Prednisone | 95 | 60 |
| Spironolactone | Spironolactone | 91 | 31 |
| Finasteride | Finasteride | 89 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 13 |
| Torsemide | Torsemide | 83 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 24 |
| Warfarin Sodium | Warfarin Sodium | 82 | 31 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 17 |
| Pregabalin | Pregabalin | 79 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 27 |
| Baclofen | Baclofen | 73 | 26 |
| Ipratropium Bromide | Ipratropium Bromide | 72 | 19 |
| Synthroid | Levothyroxine Sodium | 72 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 70 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 29 |
| Clonidine Hcl | Clonidine Hcl | 67 | 16 |
| Buspirone Hcl | Buspirone Hcl | 65 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 18 |
| Cephalexin | Cephalexin | 63 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 18 |
| Cholestyramine | Cholestyramine (With Sugar) | 61 | 26 |
| Propranolol Hcl | Propranolol Hcl | 61 | 17 |
| Xarelto | Rivaroxaban | 61 | 12 |
| Farxiga | Dapagliflozin Propanediol | 58 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 18 |
| Mirtazapine | Mirtazapine | 57 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 21 |
| Sertraline Hcl | Sertraline Hcl | 54 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 14 |
| Repatha Sureclick | Evolocumab | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 30 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 20 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Bupropion Xl | Bupropion Hcl | 48 | 15 |
| Ondansetron Odt | Ondansetron | 48 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 48 | 48 |
| Famciclovir | Famciclovir | 47 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 14 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 14 |
| Ramipril | Ramipril | 44 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 34 |
| Famotidine | Famotidine | 42 | 11 |
| Zenpep | Lipase/Protease/Amylase | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Valsartan | Valsartan | 40 | 12 |
| Sucralfate | Sucralfate | 39 | 12 |
| Novolog Flexpen | Insulin Aspart | 38 | 12 |
| Temazepam | Temazepam | 37 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 37 | 24 |
| Valacyclovir | Valacyclovir Hcl | 37 | 13 |
| Azelastine Hcl | Azelastine Hcl | 36 | 11 |
| Atenolol | Atenolol | 35 | suppressed |
| Nystatin | Nystatin | 35 | 20 |
| Rizatriptan | Rizatriptan Benzoate | 35 | suppressed |
| Metronidazole | Metronidazole | 34 | 26 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 22 |
| Premarin | Estrogens, Conjugated | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 25 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Haloperidol | Haloperidol | 28 | suppressed |
| Trimethoprim | Trimethoprim | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 14 |
| Acyclovir | Acyclovir | 24 | 11 |
| Budesonide Dr | Budesonide | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Savella | Milnacipran Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nadolol | Nadolol | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zolmitriptan | Zolmitriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,028.23 · 49 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BEXSERO, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, LifeVest, MINIMED 780G, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, PROCLAIM, Rybelsus, SAPIEN 3 Ultra RESILIA, The Cologuard Plus Collection Kit, Wegovy, ZAVZPRET, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error